Dianthus Therapeutics on Monday shared positive mid-stage data in generalized myasthenia gravis for an antibody candidate that it believes has “pipeline-in-a-product” potential for neuromuscular diseases.
The drug, called claseprubart, hit multiple efficacy endpoints in the ...
↧